Sanofi SA (NYSE:SNY) major shareholder Sanofi acquired 81,250 shares of the business’s stock in a transaction that occurred on Tuesday, July 28th. The shares were bought at an average price of $16.00 per share, with a total value of $1,300,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Major shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.
Sanofi also recently made the following trade(s):
- On Tuesday, June 9th, Sanofi sold 120,234 shares of Sanofi stock. The shares were sold at an average price of $597.48, for a total value of $71,837,410.32.
- On Friday, May 29th, Sanofi sold 20,421,899 shares of Sanofi stock. The shares were sold at an average price of $509.85, for a total value of $10,412,105,205.15.
Shares of SNY opened at $52.45 on Friday. The stock has a market capitalization of $131.34 billion, a price-to-earnings ratio of 16.76, a price-to-earnings-growth ratio of 2.41 and a beta of 0.67. Sanofi SA has a 1 year low of $37.62 and a 1 year high of $55.00. The business’s 50 day simple moving average is $51.68 and its 200-day simple moving average is $48.67. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.22 and a quick ratio of 0.85.
SNY has been the subject of several recent analyst reports. Morgan Stanley restated an “overweight” rating on shares of Sanofi in a research note on Tuesday, June 9th. Zacks Investment Research upgraded Sanofi from a “hold” rating to a “buy” rating and set a $50.00 price target for the company in a research note on Monday, May 18th. UBS Group restated a “buy” rating on shares of Sanofi in a research note on Tuesday, May 26th. Barclays restated an “equal weight” rating on shares of Sanofi in a research note on Tuesday, April 28th. Finally, JPMorgan Chase & Co. restated an “overweight” rating on shares of Sanofi in a research note on Friday. Four equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Sanofi presently has a consensus rating of “Buy” and a consensus price target of $54.00.
Sanofi Company Profile
Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.
Recommended Story: Why are percentage decliners important?
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.